

FIG 1




FIG 2




FIG 3




FIG 4











FIG 5A




BR16796




**BRI6797**



BRI6798




BR16799




BR16800


FIG 5B




**BRI6801**




**BRI6802**



**BRIX114**




**BRI6803**




**BRI6814**


**FIG 5C**




**BRI6815**




**BRI6816**



**BRI6817**




**BRI6822**




**BRI6823**


**FIG 5D**




BRI6824




BRI6825



BRI6829








BRI6855




BRI6856

FIG 5E




**BRI7001 R = NH<sub>2</sub>**  
**BRI7002 R = NH<sub>3</sub>Cl**

**FIG 5F**




BRI7009



BRI7012

FIG 5G


Inhibition or enhancement of Fc $\gamma$ RIIa binding to human IgG1.



Serial dilutions of compounds at specified concentrations, prefix BR1 and designated as indicated, were preincubated with receptor and injected over IgG and extent of receptor binding determined (shown as Response Units - Y axis).

FIG 6


Inhibition or enhancement of Fc $\gamma$ RIIa binding to human IgG3.



Serial dilutions of compounds at specified concentrations, prefix BRI and designated as indicated, were preincubated with receptor and injected over IgG and extent of receptor binding determined (shown as Response Units - Y axis).

FIG 7


Inhibition or enhancement of Fc<sub>γ</sub>RIIa binding to human IgG1.



Serial dilutions of compounds at specified concentrations, prefix BRI and designated as indicated, were preincubated with receptor and injected over IgG and extent of receptor binding determined (shown as Response Units - Y axis).

FIG 8

Inhibition or enhancement of Fc $\gamma$ RIIa binding to human IgG3.



Serial dilutions of compounds at specified concentrations, prefix BRI and designated as indicated, were preincubated with receptor and injected over IgG and extent of receptor binding determined (shown as Response Units - Y axis).

FIG 9




FIG 10

Inhibition of sFc $\gamma$ RIIa binding






FIG 11



Activation of platelets in the presence of agonist only.  
Platelets ( $100 \times 10^6/\text{ml}$ ) were mixed in the presence of Fc $\gamma$ RIa agonist (HAGG, 200 $\mu\text{g}/\text{ml}$ ) and PBS and the rate of platelet aggregation was measured as the gradient of the change to percent light transmission (x) over time (y).

FIG 12



Activation of platelets in the presence of agonist and BRI compound 6855.  
Platelets ( $100 \times 10^6/\text{ml}$ ) were mixed in the presence of Fc $\gamma$ RIa agonist (HAGG, 200 $\mu\text{g}/\text{ml}$ ) and compound BRI 6855 (5mg/ml) and the rate of platelet aggregation was measured as the gradient of the change to percent light transmission (x) over time (y).

FIG 13

**Effect of BRI compound 6728 on platelet aggregation with HAGG**




FIG 14